summarize sample characteristics, analyze feasibility/acceptability, and summarize secondary outcomes. We compared self-efficacy scores preintervention and postintervention using multilevel models (MIXED function). Results Of 36 eligible and contactable
Search Results
Re-Engage: A Novel Nurse-Led Program for Survivors of Childhood Cancer Who Are Disengaged From Cancer-Related Care
Christina Signorelli, Claire E. Wakefield, Karen A. Johnston, Joanna E. Fardell, Jordana K McLoone, Mary-Ellen E. Brierley, Maria Schaffer, Elysia Thornton-Benko, Afaf Girgis, W. Hamish Wallace, Richard J. Cohn, and on behalf of the BSU Implementation Group*
Understanding Comorbidity Profiles and Their Effect on Treatment and Survival in Patients With Colorectal Cancer
Erin E. Hahn, Michael K. Gould, Corrine E. Munoz-Plaza, Janet S. Lee, Carla Parry, and Ernest Shen
adjusted for multiple pairwise comparisons between comorbidity classes by using the Bonferroni correction. Table 1. Patient Characteristics, Cancer Treatment, and Comorbidities Results We identified 7,803 patients with CRC ( Table 1
Subdivision of M1 Stage for De Novo Metastatic Breast Cancer to Better Predict Prognosis and Response to Primary Tumor Surgery
Caijin Lin, Jiayi Wu, Shuning Ding, Chihwan Goh, Lisa Andriani, Shuangshuang Lu, Kunwei Shen, and Li Zhu
than stage IV, unknown demographic characteristics and follow-up, or unknown involvement of bone, brain, liver, or lung, and those diagnosed at autopsy or via death certificate were excluded. Eligible patients were divided randomly into the training or
Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instability–High Gastric Cancer: A Case Series
Louisa Liu, Yanghee Woo, Massimo D’Apuzzo, Laleh Melstrom, Mustafa Raoof, Yu Liang, Michelle Afkhami, Stanley R. Hamilton, and Joseph Chao
of expression. After 3 cycles of pembrolizumab, restaging PET/CT demonstrated greater diminishment of the antral tumor and stable intrathoracic nodes. Table 1. Summary of Patient Characteristics, Treatments, and Responses Figure 1
Regional Variations in Clinical Trial Outcomes in Oncology
Brooke E. Wilson, Sallie-Anne Pearson, Michael B. Barton, and Eitan Amir
breast (n=23; 16%). The mean number of participating patients, sites, and countries were similar between studies that presented regional analyses and those that did not ( Table 1 ). Table 1. Baseline Trial Characteristics (N=147) Among all 147
Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505
Jordan M. Cloyd, Sarah Colby, Katherine A. Guthrie, Andy M. Lowy, E. Gabrielle Chiorean, Phillip Philip, Davendra Sohal, and Syed Ahmad
not available for analysis. Univariate analysis was applied to compare characteristics of participants who did and did not undergo surgical resection using Student t tests for continuous variables and Fisher exact for categorical variables
The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids
Neil J. Shah, Michael R. Cook, Tianmin Wu, Shaked Lev-Ari, Matthew J. Blackburn, Michael T. Serzan, Adil Alaoui, Jaeil Ahn, and Michael B. Atkins
reported. A Bonferroni-adjusted type I error 2.5% (5%/2) was used for statistical significance. R version 3.4 (R Foundation for Statistical Computing) was used for all statistical analyses. Results Patient Characteristics, irAEs, and Use of SS and
Survival Advantage With Adjuvant Chemotherapy for Locoregionally Advanced Rectal Cancer: A Veterans Health Administration Analysis
Daphna Y. Spiegel, Matthew J. Boyer, Julian C. Hong, Christina D. Williams, Michael J. Kelley, Joseph K. Salama, and Manisha Palta
resection and consideration of adjuvant chemotherapy (AC) based on patient and tumor characteristics. The role of AC in colon cancer is supported by the results of NSABP C01, 1 a pooled analysis, 2 and the MOSAIC trial 3 showing improvement in disease
Reassessing the Net Benefit of Cancer Drugs With Evolution of Evidence Using the ASCO Value Framework
Seanthel Delos Santos, Noah Witzke, Bishal Gyawali, Vanessa Sarah Arciero, Amanda Putri Rahmadian, Louis Everest, Matthew C. Cheung, and Kelvin K. Chan
assessed at the time of primary publication and at 3 years post-FDA approval using all publicly available data in eligible subsequent publications. Results Characteristics of Included Studies Of 113 indications that met the eligibility criteria, there were
Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma
Ritesh R. Kotecha, Ronan Flippot, Taylor Nortman, Annalisa Guida, Sujata Patil, Bernard Escudier, Robert J. Motzer, Laurence Albiges, and Martin H. Voss
clinical variables. R version 3.6.1 (R Foundation for Statistical Computing) was used for statistical analyses. Results Patient Characteristics From 2001 through 2019, 68 clinical trials conducted at Gustave Roussy and Memorial Sloan Kettering